



Leqembi in the UAE

The MoHAP named-patient coordination pathway — indicative 2026

NEUROLOGY · EARLY ALZHEIMER'S DISEASE (MCI, MILD AD)

The clinical situation

Leqembi (lecanemab-irmb) is an IV anti-amyloid-beta-protofibril monoclonal antibody FDA-approved for early Alzheimer's disease (mild cognitive impairment due to AD or mild AD dementia) with confirmed amyloid pathology. Manufactured by Eisai and Biogen. Dosing is 10 mg/kg IV every 2 weeks. Pre-treatment requires amyloid confirmation (PET or CSF), baseline MRI, ApoE genotyping, and ARIA (amyloid-related imaging abnormalities) monitoring with serial MRI during the first year per FDA labelling.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your neurologist or geriatrician documents MCI/mild-AD stage, cognitive assessment, and Leqembi rationale.
- 2 Amyloid & MRI workup.** Amyloid PET or CSF confirmation, baseline MRI, ApoE genotyping, and ARIA-risk counselling completed per FDA labelling.
- 3 MoHAP named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, dosing calendar, infusion-facility plan, and chain-of-custody commitment.
- 4 US-side sourcing & cold-chain logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with validated 2–8°C shipment.
- 5 Arrival & first infusion.** Infusion facility administers first dose with ongoing ARIA surveillance MRI at labelled intervals.

Indicative economics

Reference US cash-pay range: USD 26,000–30,000 per year of Leqembi (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete MoHAP application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody from Eisai/Biogen authorised distribution.

Documentation. Physician kit tailored to MoHAP / DHA / DoH review, with anti-amyloid ARIA-monitoring annex. **Logistics.**

Validated cold-chain internationally tracked shipment. **Concierge case lead.** Named point of contact for family and physician through the titration and maintenance arc. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Leqembi × UAE first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/leqembi-uae.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team